<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="145703">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203826</url>
  </required_header>
  <id_info>
    <org_study_id>ENB-008-10</org_study_id>
    <nct_id>NCT01203826</nct_id>
  </id_info>
  <brief_title>Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)</brief_title>
  <official_title>Extension Study of Protocol ENB-006-09 Evaluating the Long-term Safety and Efficacy of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Children With Hypophosphatasia (HPP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the long term safety and efficacy of asfotase alfa in children
      with HPP who completed the ENB-006-09 study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asfotase alfa was formerly referred to as ENB-0040

      Hypophosphatasia (HPP) is a life-threatening, genetic, and ultra-rare metabolic disease
      characterized by defective bone mineralization and impaired phosphate and calcium regulation
      that can lead to progressive damage to multiple vital organs, including destruction and
      deformity of bones, profound muscle weakness, seizures, impaired renal function, and
      respiratory failure. There are no approved disease-modifying treatments for patients with
      this disease. There is also limited data available on the natural course of this disease
      over time, particularly in patients with the juvenile-onset form.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal radiograph using a qualitative Radiographic Global Impression of Change (RGI-C)scale compared to baseline of treatment in ENB-006-09.</measure>
    <time_frame>60 months</time_frame>
    <description>The time points will be pre-treatment (Baseline from the 006 study) to Month 60 of the 008 study which represents 66 months of treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypophosphatasia (HPP)</condition>
  <arm_group>
    <arm_group_label>asfotase alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>asfotase alfa 6 mg/kg/week SC injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Asfotase Alfa</intervention_name>
    <arm_group_label>asfotase alfa</arm_group_label>
    <other_name>human recombinant tissue non-specific alkaline phosphatase fusion protein</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Compliant and satisfactory completion of Enobia-sponsored clinical trial ENB-006-09

          -  Written informed consent by parent or other legal guardian prior to any study
             procedures being performed

          -  Parent or other legal guardian willing to comply with study requirements

        Exclusion Criteria:

          -  Clinically significant disease that precludes study participation, in the
             Investigator's opinion

          -  Treatment with an investigational drug other than Asfotase Alfa

          -  Enrollment in any study involving an investigational drug, device, or treatment for
             HPP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shriner's Hospital for Children</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3B 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hypophosphatasia.com</url>
    <description>Hypophosphatasia Website</description>
  </link>
  <link>
    <url>http://www.hypophosphatasia.com/hcp/</url>
    <description>Hypophosphatasia Website for Healthcare Providers</description>
  </link>
  <link>
    <url>http://www.hypophosphatasie.com</url>
    <description>Hypophosphatasie Europe</description>
  </link>
  <link>
    <url>http://www.magicfoundation.org</url>
    <description>HPP support group</description>
  </link>
  <link>
    <url>http://health.groups.yahoo.com/group/Hyphosphatasia</url>
    <description>Yahoo health group for HPP with an international list serve where patients can correspond and post questions to the group</description>
  </link>
  <link>
    <url>http://www.softbones.org</url>
    <description>US Hypophosphatasia Group (Soft Bones)</description>
  </link>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 1, 2016</lastchanged_date>
  <firstreceived_date>September 15, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypophosphatasia</keyword>
  <keyword>HPP</keyword>
  <keyword>Bone Disease</keyword>
  <keyword>Soft Bones</keyword>
  <keyword>Low Alkaline Phosphatase</keyword>
  <keyword>genetic metabolic disorder</keyword>
  <keyword>alkaline phosphatase</keyword>
  <keyword>tissue non-specific alkaline phosphatase</keyword>
  <keyword>rickets</keyword>
  <keyword>osteomalacia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypophosphatasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
